Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose ALGRX 4975 for acute lateral epicondylitis
2004-001000-12Phase 2Completed
- Sponsor
- AlgoRx Pharmaceuticals
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Lateral Epicondylitis (LET) comparing ALGRX 4975 with Placebo (2 arms). Primary endpoint: Pain induced by resisted wrist dorsiflexion at 4 weeks. Started Oct 2004; status: completed.
02
Drugs
capsaicin
03
Conditions
Lateral Epicondylitis (LET)
Beyond the preview
Go deeper on 2004-001000-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001000-12.